SCHEDULE 13G: RTW Investments and Dr. Roderick Wong Disclose 5.2% Stake in Oruka Therapeutics
Beneficial Ownership Report
RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a beneficial ownership of 5.2% of Oruka Therapeutics, Inc.'s Common Stock.
Summary
- RTW Investments, LP and Roderick Wong, M.D. (collectively, the "Reporting Persons") have filed a Schedule 13G, disclosing their beneficial ownership in Oruka Therapeutics, Inc.
- The Reporting Persons collectively beneficially own 1,945,649 shares of Oruka Therapeutics, Inc. Common Stock.
- This ownership represents 5.2% of the outstanding Common Stock of Oruka Therapeutics, Inc.
- The percentage is calculated based on 37,440,510 shares outstanding as of February 28, 2025, as reported in the Company's Annual Report on Form 10-K filed on March 6, 2025.
- RTW Investments, LP is a Delaware limited partnership and an investment adviser to certain funds (the "RTW Funds").
- Roderick Wong, M.D. is the Managing Partner and Chief Investment Officer of RTW Investments.
- The shares are held by the RTW Funds, and the Reporting Persons share voting and dispositive power over these shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently convey positive or negative sentiment regarding the company's performance or prospects. It is a neutral regulatory filing.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant passive investment by an institutional investor in a publicly traded company. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake (5.2%) by an established investment firm like RTW Investments may be viewed positively by other shareholders, indicating institutional confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 2025-02-28 | Date as of which 37,440,510 shares of Oruka Therapeutics, Inc. Common Stock were outstanding, as reported in the Company's 10-K. |
| 2025-03-06 | Date Oruka Therapeutics, Inc. filed its Annual Report on Form 10-K with the SEC. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-05-15 | Date the Schedule 13G statement was signed by RTW Investments, LP and Roderick Wong, M.D. |
Keywords
Oruka Therapeutics, RTW Investments, Roderick Wong, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.